Deal

Seed Capital invests in Reapplix

The Danish company Reapplix has received an investment of DKK 7.6 million from SEED Capital.

Reapplix was founded in 2008 and has developed the product LeucoPatch for treatment of severe chronic foot ulcers. The product has revealed promising results on up to 10 year old wounds in a clinic study.

SEED Capital's investment will be used to conduct additional clinical efficacy studies of LeucoPatch on diabetic foot ulcers and prepare for commercialization of the product. Reapplix is the first investment from the newly raised SEED Capital Denmark II.

Read more


FundSEED Capital Fund II
Portfolio CompanyReapplix
Date of Transaction2010-09-02
TransactionAcquisition, Finance round
Seller
Buyer
Size of TransactionDKK 7.6m
Ind. FocusLife Science
GeographyDenmark
StageSeed
 

More deals

(2011-07-13)